Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.17 Billion INR | -26.34% |
| 2022 | 1.57 Billion INR | 1.16% |
| 2021 | 1.55 Billion INR | 9.0% |
| 2020 | 1.42 Billion INR | 26.62% |
| 2019 | 1.12 Billion INR | 9.71% |
| 2018 | 1.02 Billion INR | 18.5% |
| 2017 | 864.95 Million INR | 35.09% |
| 2016 | 640.27 Million INR | -22.75% |
| 2015 | 828.81 Million INR | 247.89% |
| 2014 | 238.24 Million INR | -71.62% |
| 2013 | 839.49 Million INR | -4.47% |
| 2012 | 878.76 Million INR | 0.0% |
| 2010 | 2.02 Billion INR | 32.8% |
| 2009 | 1.52 Billion INR | 8.8% |
| 2008 | 1.4 Billion INR | 6.99% |
| 2007 | 1.31 Billion INR | 36.82% |
| 2006 | 957.85 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 248.45 Million INR | -30.81% |
| 2023 FY | 1.15 Billion INR | -26.34% |
| 2023 Q4 | 359.12 Million INR | 88.68% |
| 2023 Q3 | 190.33 Million INR | -64.26% |
| 2023 Q2 | 532.58 Million INR | -7.95% |
| 2023 Q1 | 578.6 Million INR | 382.76% |
| 2022 Q4 | 119.85 Million INR | -78.59% |
| 2022 Q3 | 559.84 Million INR | 18.57% |
| 2022 Q2 | 472.17 Million INR | 12.91% |
| 2022 Q1 | 418.16 Million INR | 116.71% |
| 2022 FY | 1.57 Billion INR | 1.16% |
| 2021 Q3 | 487.93 Million INR | 6.88% |
| 2021 Q1 | 414.46 Million INR | 142.28% |
| 2021 Q2 | 456.51 Million INR | 10.15% |
| 2021 FY | 1.55 Billion INR | 9.0% |
| 2021 Q4 | 192.96 Million INR | -60.45% |
| 2020 FY | 1.42 Billion INR | 26.62% |
| 2020 Q1 | 312.74 Million INR | 1328.11% |
| 2020 Q2 | 437.23 Million INR | 39.81% |
| 2020 Q3 | 495.44 Million INR | 13.31% |
| 2020 Q4 | 171.07 Million INR | -65.47% |
| 2019 FY | 1.12 Billion INR | 9.71% |
| 2019 Q3 | 439.43 Million INR | 29.37% |
| 2019 Q4 | 21.89 Million INR | -95.02% |
| 2019 Q1 | 323.57 Million INR | 355.04% |
| 2019 Q2 | 339.66 Million INR | 4.97% |
| 2018 FY | 1.02 Billion INR | 18.5% |
| 2018 Q3 | 264.17 Million INR | -18.14% |
| 2018 Q4 | 71.1 Million INR | -73.08% |
| 2018 Q2 | 322.69 Million INR | -16.75% |
| 2018 Q1 | 387.64 Million INR | 820.0% |
| 2017 Q4 | 42.13 Million INR | -87.08% |
| 2017 Q1 | 218.57 Million INR | 5.41% |
| 2017 FY | 864.95 Million INR | 35.09% |
| 2017 Q3 | 326.21 Million INR | 0.0% |
| 2016 Q1 | 250.7 Million INR | 555.47% |
| 2016 Q3 | 244.31 Million INR | -15.25% |
| 2016 Q2 | 288.28 Million INR | 14.99% |
| 2016 Q4 | 207.35 Million INR | -15.13% |
| 2016 FY | 640.27 Million INR | -22.75% |
| 2015 FY | 828.81 Million INR | 247.89% |
| 2015 Q2 | 251.2 Million INR | 102.3% |
| 2015 Q4 | -55.04 Million INR | -124.83% |
| 2015 Q3 | 221.68 Million INR | -11.75% |
| 2015 Q1 | 124.17 Million INR | 141.95% |
| 2014 Q2 | 192.08 Million INR | -6.32% |
| 2014 FY | 238.24 Million INR | -71.62% |
| 2014 Q4 | -296.03 Million INR | -315.85% |
| 2014 Q3 | 137.14 Million INR | -28.6% |
| 2014 Q1 | 205.04 Million INR | 997.59% |
| 2013 Q2 | 229.39 Million INR | -22.22% |
| 2013 FY | 839.49 Million INR | -4.47% |
| 2013 Q1 | 294.92 Million INR | 199.79% |
| 2013 Q3 | 296.49 Million INR | 29.25% |
| 2013 Q4 | 18.68 Million INR | -93.7% |
| 2012 Q4 | 98.37 Million INR | -70.23% |
| 2012 FY | 878.76 Million INR | 0.0% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q2 | 453.09 Million INR | 0.0% |
| 2012 Q3 | 330.41 Million INR | -27.07% |
| 2010 FY | 2.02 Billion INR | 32.8% |
| 2009 FY | 1.52 Billion INR | 8.8% |
| 2008 FY | 1.4 Billion INR | 6.99% |
| 2007 FY | 1.31 Billion INR | 36.82% |
| 2006 FY | 957.85 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 91.888% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 98.595% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 82.526% |
| Granules India Limited | 16.79 Billion INR | 87.068% |
| Indoco Remedies Limited | 6.04 Billion INR | 64.039% |
| Achyut Healthcare Limited | 4.86 Million INR | -44593.088% |
| Ajanta Pharma Limited | 21.06 Billion INR | 89.686% |
| Alkem Laboratories Limited | 52.29 Billion INR | 95.846% |
| Alpa Laboratories Limited | 188.89 Million INR | -1050.126% |
| Brooks Laboratories Limited | 65.62 Million INR | -3210.776% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 65.087% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -47.61% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 41.21% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 98.672% |
| Eris Lifesciences Limited | 10.42 Billion INR | 79.164% |
| FDC Limited | 8.33 Billion INR | 73.934% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 96.867% |
| Gufic Biosciences Limited | 4.16 Billion INR | 47.872% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 64.927% |
| Ipca Laboratories Limited | 29.8 Billion INR | 92.712% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -232.909% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -1027.258% |
| Lasa Supergenerics Limited | 121.02 Million INR | -1695.035% |
| Laurus Labs Limited | 24.62 Billion INR | 91.176% |
| Lupin Limited | 123.71 Billion INR | 98.244% |
| Mankind Pharma Limited | 44.52 Billion INR | 95.12% |
| Medicamen Biotech Limited | 495.49 Million INR | -338.457% |
| Medico Remedies Limited | 262.14 Million INR | -728.755% |
| Megasoft Limited | 342.07 Million INR | -535.111% |
| NATCO Pharma Limited | 25.73 Billion INR | 91.558% |
| Piramal Pharma Limited | 24.47 Billion INR | 91.122% |
| RPG Life Sciences Limited | 2.48 Billion INR | 12.504% |
| Sigachi Industries Limited | 2 Billion INR | -8.503% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.16% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 47.311% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -130.532% |
| Unichem Laboratories Limited | 4.86 Billion INR | 55.343% |
| Wanbury Limited | 1.73 Billion INR | -25.533% |
| Windlas Biotech Limited | 1.33 Billion INR | -62.274% |
| ZIM Laboratories Limited | 1.26 Billion INR | -71.486% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 98.265% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 460.642% |
| Divi's Laboratories Limited | 32.44 Billion INR | 93.303% |
| Hester Biosciences Limited | 1.27 Billion INR | -70.575% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 62.422% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -39.575% |
| Bal Pharma Limited | 770.19 Million INR | -182.075% |
| Strides Pharma Science Limited | 14.38 Billion INR | 84.901% |
| Venus Remedies Limited | 2.18 Billion INR | 0.461% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 62.744% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 26.902% |
| Shilpa Medicare Limited | 3.54 Billion INR | 38.748% |
| Aarti Drugs Limited | 8.31 Billion INR | 73.876% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 52.573% |
| Suven Life Sciences Limited | -200.79 Million INR | 1181.954% |
| Valiant Laboratories Limited | -60.66 Million INR | 3681.252% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 90.429% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -152.268% |
| Themis Medicare Limited | 1.5 Billion INR | -44.459% |
| Hikal Limited | 3.14 Billion INR | 30.879% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 95.354% |
| Sequent Scientific Limited | 2.97 Billion INR | 27.065% |
| Novartis India Limited | 1.32 Billion INR | -63.73% |
| Wockhardt Limited | 16.24 Billion INR | 86.622% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 88.94% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -14801.068% |
| Neuland Laboratories Limited | 8.24 Billion INR | 73.659% |
| Morepen Laboratories Limited | 6.16 Billion INR | 64.739% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -250.139% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -208.771% |